Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia
Abstract
- Publication:
-
PLoS ONE
- Pub Date:
- February 2014
- DOI:
- 10.1371/journal.pone.0089080
- Bibcode:
- 2014PLoSO...989080O